One dose for every body? Rethinking drug exposure
Dr. Jiha Lee | Size Matters Session | ACR 2026
Transcription
Hi, I'm Ji Halei reporting from RheumNow for ACR 2026 in sunny lovely Orlando, Florida.
So, I have a question for you. If you have a patient with 70 kg compared to somebody who's 110 kg, would you treat them the same way? And do you expect them to have the same response to the medications you give them? Well, according to the sessions, size matters. Maybe we shouldn't. And maybe because of weight, we're underdosing our patients.
Well, obesity — there's a lot of content here at ACR and it's very important to consider for our patients, because 70 to 80% of patients with psoriatic arthritis are obese or overweight. And there's been multiple studies to show that obese patients have worse disease activity and may not respond to treatment the same way. And some of that answer may lie in obesity and also fat cells and how it impacts drug clearance. Because drug effect is simple: it's drug exposure divided by clearance, and obesity makes patients clear faster.
So in this session they modeled to say that somebody who's 70 kgs and receiving adalimumab may need up to 40% more medication to get the same drug effect. And it's not just for adalimumab that we see this — it's for other monoclonal drugs as well, and also drugs like IL-6 inhibitors as well as JAK inhibitors.
Now, the one exception — and this wasn't discussed during ACR, I looked up the study — goodness gracious, I am stalling, I am so sorry for that — it is the ACQUIRE study. The ACQUIRE study was looking at abatacept, and this was a post-hoc analysis of their trial, and what they showed was that abatacept regardless of body weight held the dose steady, both in subcutaneous form and IV form.
So what does that mean for our patients? Like all of our drugs, mostly are fixed dosing, and by doing so we may be underdosing. And our first lines are anti-TNFs and they're majorly affected. So maybe we need to take a different tiered approach for somebody who is obese. Some of the approaches you can do is prioritizing IV drugs, provided they're cleared and paid for by insurance, and for example, like adalimumab — instead of doing every two weeks, increasing to a weekly dose sooner than later, so our patients have better achievement. And checking drug levels when they are available.
Now, understanding how obesity affects drug clearance — my question then is, along with obesity, we've seen a lot of content about GLP-1, and I'm sure, like my patients, yours are on GLP-1. So what does it mean when they're on that and losing weight? How do we adjust dose, and how do we separate the effects of disease activity improving because of GLP-1 and weight loss versus drugs having better clearance? And that's the story for my other two videos coming up.
Thank you for listening. This is Ji Halei for RheumNow.
So, I have a question for you. If you have a patient with 70 kg compared to somebody who's 110 kg, would you treat them the same way? And do you expect them to have the same response to the medications you give them? Well, according to the sessions, size matters. Maybe we shouldn't. And maybe because of weight, we're underdosing our patients.
Well, obesity — there's a lot of content here at ACR and it's very important to consider for our patients, because 70 to 80% of patients with psoriatic arthritis are obese or overweight. And there's been multiple studies to show that obese patients have worse disease activity and may not respond to treatment the same way. And some of that answer may lie in obesity and also fat cells and how it impacts drug clearance. Because drug effect is simple: it's drug exposure divided by clearance, and obesity makes patients clear faster.
So in this session they modeled to say that somebody who's 70 kgs and receiving adalimumab may need up to 40% more medication to get the same drug effect. And it's not just for adalimumab that we see this — it's for other monoclonal drugs as well, and also drugs like IL-6 inhibitors as well as JAK inhibitors.
Now, the one exception — and this wasn't discussed during ACR, I looked up the study — goodness gracious, I am stalling, I am so sorry for that — it is the ACQUIRE study. The ACQUIRE study was looking at abatacept, and this was a post-hoc analysis of their trial, and what they showed was that abatacept regardless of body weight held the dose steady, both in subcutaneous form and IV form.
So what does that mean for our patients? Like all of our drugs, mostly are fixed dosing, and by doing so we may be underdosing. And our first lines are anti-TNFs and they're majorly affected. So maybe we need to take a different tiered approach for somebody who is obese. Some of the approaches you can do is prioritizing IV drugs, provided they're cleared and paid for by insurance, and for example, like adalimumab — instead of doing every two weeks, increasing to a weekly dose sooner than later, so our patients have better achievement. And checking drug levels when they are available.
Now, understanding how obesity affects drug clearance — my question then is, along with obesity, we've seen a lot of content about GLP-1, and I'm sure, like my patients, yours are on GLP-1. So what does it mean when they're on that and losing weight? How do we adjust dose, and how do we separate the effects of disease activity improving because of GLP-1 and weight loss versus drugs having better clearance? And that's the story for my other two videos coming up.
Thank you for listening. This is Ji Halei for RheumNow.
Recommended videos
-
Education/ACR/EULAR
Day 1 Recap: ACR Convergence 26
-
Psoriatic Arthritis
Incidence of Obesity/Overweight in PsA: Four in Five
-

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.